Consolidated Statements of Changes in Shareholders' Deficit - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
| Preferred Stock [Member] | Series A Preferred Stock [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
$ 500
|
$ 500
|
| Balance, shares |
5,000,000
|
5,000,000
|
| Issuance of common stock upon conversion |
|
|
| Conversion of Series B PS to common stock |
|
|
| Conversion of Series D PS to common stock |
|
|
| Exchange of Series D PS to Series E PS |
|
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
|
| Exercise of warrants related to the sale of common shares |
|
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
|
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
|
|
| Redemption of Series D Preferred shares |
|
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
|
| Common shares to be issued for Patent acquisition |
|
|
| Common stock vested to consultants |
|
|
| Common stock issued to consultants |
|
|
| Common stock issued to employees |
|
|
| Common shares to be issued for Technical Rights Agreement |
|
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
|
| Conversion of Series E Preferred Shares to common stock |
|
|
| Dividends payable on Preferred Shares |
|
|
| Series B PS Dividends in kind issued |
|
|
| Accretion of Series E Preferred Shares |
|
|
| Common shares issued for Technical Rights Agreement |
|
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
|
| Reclassification of warrants to liability |
|
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for financing expense |
|
|
| Net loss |
|
|
| Issuance of common shares under financing agreement |
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
|
|
| Common stock issued in business agreement |
|
|
| Common stock issued from shares payable |
|
|
| Balance, value |
$ 500
|
$ 500
|
| Balance, shares |
5,000,000
|
5,000,000
|
| Preferred Stock [Member] | Series B Preferred Stock [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
|
|
| Balance, shares |
|
607
|
| Issuance of common stock upon conversion |
|
|
| Conversion of Series B PS to common stock |
|
|
| Conversion of Series B PS to common stock, shares |
|
(839)
|
| Conversion of Series D PS to common stock |
|
|
| Exchange of Series D PS to Series E PS |
|
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
|
| Exercise of warrants related to the sale of common shares |
|
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
|
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
|
|
| Redemption of Series D Preferred shares |
|
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
|
| Common shares to be issued for Patent acquisition |
|
|
| Common stock vested to consultants |
|
|
| Common stock issued to consultants |
|
|
| Common stock issued to employees |
|
|
| Common shares to be issued for Technical Rights Agreement |
|
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
|
| Conversion of Series E Preferred Shares to common stock |
|
|
| Dividends payable on Preferred Shares |
|
|
| Series B PS Dividends in kind issued |
|
|
| Series B PS Dividends in kind issued, shares |
|
232
|
| Accretion of Series E Preferred Shares |
|
|
| Common shares issued for Technical Rights Agreement |
|
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
|
| Reclassification of warrants to liability |
|
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for financing expense |
|
|
| Net loss |
|
|
| Issuance of common shares under financing agreement |
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
|
|
| Common stock issued in business agreement |
|
|
| Common stock issued from shares payable |
|
|
| Balance, value |
|
|
| Balance, shares |
|
|
| Common Stock [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
$ 67,500
|
$ 56,075
|
| Balance, shares |
674,644,124
|
560,745,180
|
| Issuance of common stock upon conversion |
|
$ 133
|
| Issuance of common stock upon conversion, shares |
|
1,329,246
|
| Conversion of Series B PS to common stock |
|
$ 1,007
|
| Conversion of Series B PS to common stock, shares |
|
10,068,000
|
| Conversion of Series D PS to common stock |
|
$ 43
|
| Conversion of Series D PS to common stock, shares |
|
428,572
|
| Exchange of Series D PS to Series E PS |
|
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
$ 3,577
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares, shares |
|
35,772,729
|
| Exercise of warrants related to the sale of common shares |
|
$ 110
|
| Exercise of warrants related to the sale of common shares, shares |
|
1,100,000
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
|
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
|
|
| Redemption of Series D Preferred shares |
|
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
|
| Common shares to be issued for Patent acquisition |
|
|
| Common stock vested to consultants |
$ 18
|
$ 47
|
| Common stock vested to consultants, shares |
125,000
|
412,500
|
| Common stock issued to consultants |
|
$ 48
|
| Common stock issued to consultants, shares |
|
476,946
|
| Common stock issued to employees |
|
$ 18
|
| Common stock issued to employees, shares |
|
275,000
|
| Common shares to be issued for Technical Rights Agreement |
|
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
|
| Conversion of Series E Preferred Shares to common stock |
$ 1,446
|
$ 822
|
| Conversion of Series E Preferred Shares to common stock, shares |
14,458,127
|
8,228,572
|
| Dividends payable on Preferred Shares |
|
|
| Series B PS Dividends in kind issued |
|
|
| Accretion of Series E Preferred Shares |
|
|
| Common shares issued for Technical Rights Agreement |
|
$ 1,287
|
| Common shares issued for Technical Rights Agreement, shares |
|
12,871,287
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
$ 1,386
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition, shares |
|
13,861,386
|
| Reclassification of warrants to liability |
|
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for legal settlement to NSH shareholders |
$ 6,152
|
$ 2,889
|
| Common stock issued for legal settlement to NSH shareholders, shares |
61,558,203
|
28,494,706
|
| Common stock issued for financing expense |
|
$ 58
|
| Common stock issued for financing expense, shares |
|
580,000
|
| Issuance of common shares under financing agreement |
$ 5,201
|
|
| Issuance of common shares under financing agreement, shares |
52,018,294
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
25
|
|
| Common stock issued in business agreement, to be paid from revenue earned, shares |
250,000
|
|
| Common stock issued in business agreement |
$ 25
|
|
| Common stock issued in business agreement ,shares |
250,000
|
|
| Common stock issued from shares payable |
$ 10
|
|
| Common stock issued from shares payable, shares |
100,000
|
|
| Balance, value |
$ 80,377
|
$ 67,500
|
| Balance, shares |
803,403,748
|
674,644,124
|
| Additional Paid-in Capital [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
$ 96,701,607
|
$ 56,649,491
|
| Issuance of common stock upon conversion |
|
421,353
|
| Conversion of Series B PS to common stock |
|
(1,007)
|
| Conversion of Series D PS to common stock |
|
(43)
|
| Exchange of Series D PS to Series E PS |
|
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
17,273,546
|
| Exercise of warrants related to the sale of common shares |
|
10,890
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
99,000
|
3,439,219
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
|
|
| Redemption of Series D Preferred shares |
|
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
(3,087,830)
|
| Common shares to be issued for Patent acquisition |
|
|
| Common stock vested to consultants |
73,106
|
221,424
|
| Common stock issued to consultants |
|
158,285
|
| Common stock issued to employees |
|
82,954
|
| Common shares to be issued for Technical Rights Agreement |
|
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
|
| Conversion of Series E Preferred Shares to common stock |
1,666,554
|
2,879,179
|
| Dividends payable on Preferred Shares |
|
|
| Series B PS Dividends in kind issued |
|
278,400
|
| Accretion of Series E Preferred Shares |
|
|
| Common shares issued for Technical Rights Agreement |
|
4,761,089
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
6,998,614
|
| Reclassification of warrants to liability |
|
(2,935,000)
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for legal settlement to NSH shareholders |
19,439,132
|
9,413,060
|
| Common stock issued for financing expense |
|
137,982
|
| Issuance of common shares under financing agreement |
3,070,544
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
56,225
|
|
| Common stock issued in business agreement |
25,975
|
|
| Common stock issued from shares payable |
24,590
|
|
| Balance, value |
121,156,733
|
96,701,607
|
| Stock To Be Issued [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
20,132,650
|
136,000
|
| Issuance of common stock upon conversion |
|
|
| Conversion of Series B PS to common stock |
|
|
| Conversion of Series D PS to common stock |
|
|
| Exchange of Series D PS to Series E PS |
|
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
|
| Exercise of warrants related to the sale of common shares |
|
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
|
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
|
|
| Redemption of Series D Preferred shares |
|
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
2,000,000
|
| Common shares to be issued for Patent acquisition |
|
5,000,000
|
| Common stock vested to consultants |
|
|
| Common stock issued to consultants |
|
|
| Common stock issued to employees |
|
24,600
|
| Common shares to be issued for Technical Rights Agreement |
|
4,762,376
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
|
| Conversion of Series E Preferred Shares to common stock |
|
|
| Dividends payable on Preferred Shares |
|
|
| Series B PS Dividends in kind issued |
|
|
| Accretion of Series E Preferred Shares |
|
|
| Common shares issued for Technical Rights Agreement |
|
(4,762,376)
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
(7,000,000)
|
| Reclassification of warrants to liability |
|
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
29,388,000
|
| Common stock issued for legal settlement to NSH shareholders |
(19,445,284)
|
(9,415,950)
|
| Common stock issued for financing expense |
|
|
| Issuance of common shares under financing agreement |
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
|
|
| Common stock issued in business agreement |
|
|
| Common stock issued from shares payable |
(24,600)
|
|
| Balance, value |
662,767
|
20,132,650
|
| Subscription Receivable [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
|
|
| Issuance of common stock upon conversion |
|
|
| Conversion of Series B PS to common stock |
|
|
| Conversion of Series D PS to common stock |
|
|
| Exchange of Series D PS to Series E PS |
|
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
|
| Exercise of warrants related to the sale of common shares |
|
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
|
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
|
|
| Redemption of Series D Preferred shares |
|
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
|
| Common shares to be issued for Patent acquisition |
|
|
| Common stock vested to consultants |
|
|
| Common stock issued to consultants |
|
|
| Common stock issued to employees |
|
|
| Common shares to be issued for Technical Rights Agreement |
|
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
|
| Conversion of Series E Preferred Shares to common stock |
|
|
| Dividends payable on Preferred Shares |
|
|
| Series B PS Dividends in kind issued |
|
|
| Accretion of Series E Preferred Shares |
|
|
| Common shares issued for Technical Rights Agreement |
|
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
|
| Reclassification of warrants to liability |
|
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for financing expense |
|
|
| Issuance of common shares under financing agreement |
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
(56,250)
|
|
| Common stock issued in business agreement |
|
|
| Common stock issued from shares payable |
|
|
| Balance, value |
(56,250)
|
|
| Retained Earnings [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
(150,036,023)
|
(53,683,268)
|
| Issuance of common stock upon conversion |
|
|
| Conversion of Series B PS to common stock |
|
|
| Conversion of Series D PS to common stock |
|
|
| Exchange of Series D PS to Series E PS |
|
(3,258,189)
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
|
| Exercise of warrants related to the sale of common shares |
|
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
(99,000)
|
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
(113,048)
|
(3,349,198)
|
| Redemption of Series D Preferred shares |
|
(2,534,758)
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
|
| Common shares to be issued for Patent acquisition |
|
|
| Common stock vested to consultants |
|
|
| Common stock issued to consultants |
|
|
| Common stock issued to employees |
|
|
| Common shares to be issued for Technical Rights Agreement |
|
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
(182,639)
|
| Conversion of Series E Preferred Shares to common stock |
(108,000)
|
|
| Dividends payable on Preferred Shares |
(277,868)
|
(392,390)
|
| Accretion of Series E Preferred Shares |
(755,333)
|
(337,834)
|
| Common shares issued for Technical Rights Agreement |
|
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
|
| Reclassification of warrants to liability |
|
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for financing expense |
|
|
| Net loss |
(15,988,020)
|
(86,297,748)
|
| Issuance of common shares under financing agreement |
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
(156,000)
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
|
|
| Common stock issued in business agreement |
|
|
| Common stock issued from shares payable |
|
|
| Balance, value |
(167,533,292)
|
(150,036,023)
|
| Noncontrolling Interest [Member] |
|
|
| Statement [Line Items] |
|
|
| Balance, value |
|
(87,830)
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
87,830
|
| Net loss |
|
|
| Balance, value |
|
|
| Balance, value |
(33,133,765)
|
3,070,969
|
| Issuance of common stock upon conversion |
|
421,486
|
| Conversion of Series B PS to common stock |
|
|
| Conversion of Series D PS to common stock |
|
|
| Exchange of Series D PS to Series E PS |
|
(3,258,189)
|
| Sale of common shares and warrants for cash, less offering costs and commitment shares |
|
17,277,123
|
| Exercise of warrants related to the sale of common shares |
|
11,000
|
| Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized |
|
3,439,219
|
| Amortization of beneficial conversion feature related to Series E Preferred Shares |
(113,048)
|
(3,349,198)
|
| Redemption of Series D Preferred shares |
|
(2,534,758)
|
| Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity |
|
(1,000,000)
|
| Common shares to be issued for Patent acquisition |
|
5,000,000
|
| Common stock vested to consultants |
73,124
|
221,472
|
| Common stock issued to consultants |
|
158,333
|
| Common stock issued to employees |
|
107,572
|
| Common shares to be issued for Technical Rights Agreement |
|
4,762,376
|
| Revision of dividends payable on Series B Preferred Shares (See Note 2) |
|
(182,639)
|
| Conversion of Series E Preferred Shares to common stock |
1,560,000
|
2,880,001
|
| Dividends payable on Preferred Shares |
(277,868)
|
(392,390)
|
| Series B PS Dividends in kind issued |
|
278,400
|
| Accretion of Series E Preferred Shares |
(755,333)
|
(337,834)
|
| Common shares issued for Technical Rights Agreement |
|
|
| Common shares issued for acquisition of non-controlling interest and Patent acquisition |
|
|
| Reclassification of warrants to liability |
|
(2,935,000)
|
| Common stock to be issued for legal settlement to NSH shareholders |
|
29,388,000
|
| Common stock issued for legal settlement to NSH shareholders |
|
|
| Common stock issued for financing expense |
|
138,040
|
| Net loss |
(15,988,020)
|
(86,297,748)
|
| Issuance of common shares under financing agreement |
3,075,745
|
|
| Increase of 10% in Series E Preferred Shares to one holder based on certain rights |
(156,000)
|
|
| Common stock issued in business agreement, to be paid from revenue earned |
|
|
| Common stock issued in business agreement |
$ 26,000
|
|
| Common stock issued in business agreement ,shares |
100,000
|
|
| Common stock issued from shares payable |
|
|
| Balance, value |
$ (45,689,165)
|
$ (33,133,765)
|